The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches.
Macaluso, Fabio Salvatore
The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches. [electronic resource] - Inflammatory bowel diseases 01 2021 - 182-189 p. digital
Publication Type: Journal Article; Multicenter Study; Observational Study
1536-4844
10.1093/ibd/izaa036 doi
Biosimilar Pharmaceuticals--therapeutic use
Gastrointestinal Agents--therapeutic use
Humans
Inflammatory Bowel Diseases--drug therapy
Infliximab--therapeutic use
Prospective Studies
Treatment Outcome
The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches. [electronic resource] - Inflammatory bowel diseases 01 2021 - 182-189 p. digital
Publication Type: Journal Article; Multicenter Study; Observational Study
1536-4844
10.1093/ibd/izaa036 doi
Biosimilar Pharmaceuticals--therapeutic use
Gastrointestinal Agents--therapeutic use
Humans
Inflammatory Bowel Diseases--drug therapy
Infliximab--therapeutic use
Prospective Studies
Treatment Outcome